Navigation Links
Newly discovered 'scarecrow' gene might trigger big boost in food production
Date:1/24/2013

ITHACA, N.Y. With projections of 9.5 billion people by 2050, humanity faces the challenge of feeding modern diets to additional mouths while using the same amounts of water, fertilizer and arable land as today.

Cornell University researchers have taken a leap toward meeting those needs by discovering a gene that could lead to new varieties of staple crops with 50 percent higher yields.

The gene, called Scarecrow, is the first discovered to control a special leaf structure, known as Kranz anatomy, which leads to more efficient photosynthesis. Plants photosynthesize using one of two methods: C3, a less efficient, ancient method found in most plants, including wheat and rice; and C4, a more efficient adaptation employed by grasses, maize, sorghum and sugarcane that is better suited to drought, intense sunlight, heat and low nitrogen.

"Researchers have been trying to find the underlying genetics of Kranz anatomy so we can engineer it into C3 crops," said Thomas Slewinski, lead author of a paper that appeared online in the journal Plant and Cell Physiology. Slewinski is a postdoctoral researcher in the lab of senior author Robert Turgeon, professor of plant biology.

The finding "provides a clue as to how this whole anatomical key is regulated," said Turgeon. "There's still a lot to be learned, but now the barn door is open and you are going to see people working on this Scarecrow pathway."

The promise of transferring C4 mechanisms into C3 plants has been fervently pursued and funded on a global scale for decades, he added.

If C4 photosynthesis is successfully transferred to C3 plants through genetic engineering, farmers could grow wheat and rice in hotter, dryer environments with less fertilizer, while possibly increasing yields by half, the researchers said.

C3 photosynthesis originated at a time in Earth's history when the atmosphere had a high proportion of carbon dioxide. C4 plants have independen
'/>"/>

Contact: John Carberry
johncarberry@cornell.edu
607-255-5353
Cornell University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
2. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
3. Newly discovered foot points to a new kid on the hominin block
4. Newly found protein helps cells build tissues
5. Scientists advance field of research with publication of newly validated method for analyzing flavanols in cocoa
6. Key proteins newly discovered form and function may provide novel cancer treatment target
7. Newly discovered breast milk antibodies help neutralize HIV
8. Newly discovered dinosaur implies greater prevalence of feathers
9. U of M researchers: Newly discovered genetic markers could signal colon cancer development
10. ORNLs newly licensed neutron detector will advance human disease research
11. Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... new studies shed light on the complex defense mechanisms ... of which could lead to new, more effective antibiotics ... of antibiotic resistance. The studies, both of which target ... will appear in the February 17 inaugural print issue ...
... San Francisco, is just one of the many American ... trial in India. , The trial is studying ... Under Guidance): a reversible, nonhormonal contraceptive that provides 10 ... procedure. Researchers received approval this week to begin enrolling ...
... at just four months old, babies are able to ... according to brightness, shape, and how close the visual ... very young infants are much more capable of organising ... The study also has implications for understanding certain developmental ...
Cached Biology News:Pair of studies offer new clues to combat antibiotic resistance 2New male contraceptive clears hurdle 2New male contraceptive clears hurdle 3Infants can organise visual information at just four months 2Infants can organise visual information at just four months 3
(Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
(Date:12/19/2014)... 18, 2014 Egenix, Inc. is pleased to announce ... of the Board, to succeed Donald Fresne ; Mr. ... continue as a member of the Board.  In recognition of ... the company over almost twenty years, the Board designated Mr. ... Directors has established a Search Committee to find a suitable ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... 16 CEL-SCI Corporation (NYSE Amex: ... prevention and treatment of infectious diseases and a late-stage oncology ... (FDA) has indicated that the Company can proceed with its ... LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 ...
... , , EAST BRUNSWICK, N.J. Sept. 16 ... on September 14, 2009, the Company completed a Type A meeting with ... Letter (CRL) received by Savient on July 31, 2009 regarding the Company,s ... gout in patients refractory to conventional therapy. , ...
... ... FDA, including increased scrutiny of complex medical devices, automating your QA process is more ... one of the leading medical device software engineering and QA consulting firms in the ... , ...
Cached Biology Technology:CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 2CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 3CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 2Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 3Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 5Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 6Implementing QA Automation Tools in an FDA Controlled Software Environment, a Free Webinar 2
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
CCNI Antibody...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Biology Products: